We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Global Regulator of Gene Transcription Identified as Potential Anticancer Drug Target

By LabMedica International staff writers
Posted on 14 Feb 2016
The enzyme MLL1 (histone-lysine N-methyltransferase 2A) was identified as a potential target for anticancer drugs after researchers found that its inhibition prevented tumor development by shutting down the DNA damage response mechanism and suppressed inflammation by blocking the activity of proliferation-promoting genes.

MLL is a histone methyltransferase deemed a positive global regulator of gene transcription. More...
This protein belongs to the group of histone-modifying enzymes and is involved in the epigenetic maintenance of transcriptional memory. Previous observations linked this transcription-associated methyltransferase and oncoprotein to the DNA damage response (DDR), which led investigators at the University of Pennsylvania (Philadelphia, USA) to examine the role of MLL1 in cancer development and in the appearance of age-related inflammation.

They reported in the February 1, 2016, issue of the journal Genes & Development that MLL1 displayed direct epigenetic control over pro-proliferative cell cycle genes. Inhibition of MLL1 repressed expression of pro-proliferative cell cycle regulators required for DNA replication and DDR activation, thus disabling age-related inflammation expression. However, these effects of MLL1 inhibition on age-related inflammation gene expression did not impair oncogene-induced senescence (OIS) and, abolished the ability of the age-related inflammation to enhance cancer cell proliferation. These results demonstrated that MLL1 inhibition may be a powerful and effective strategy for blocking cancerous growth through the direct epigenetic regulation of proliferation-promoting genes.

"Since tumor-promoting inflammation is one of the hallmarks of cancer, these findings suggest that MLL1 inhibitors may be highly potent anticancer drugs through both direct epigenetic effects on proliferation-promoting genes, as well as through the inhibition of inflammation in the tumor microenvironment," said first author Dr. Brian Capell, a medical fellow in epigenetics and dermatology at the University of Pennsylvania. "In cancer, this could be a potent one-two punch, by blocking both proliferation-promoting genes as well as the cancerous inflammation. One could imagine taking an MLL1 inhibitor as a primary treatment, but also as an adjuvant therapy to tamp down the rampant inflammation caused by drugs like chemotherapies."

Related Links:

University of Pennsylvania



New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Collection and Transport System
PurSafe Plus®
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
New
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.